cancer

CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune…

4 months ago

Tensive appointsmedical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Has more than 30 years of experience bringing innovations to market, including one of the world’s first drug-eluting coronary stents…

4 months ago

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…

4 months ago

Leo Cancer Care Receives FDA 510(k) Clearance for Marie – A Revolutionary Upright Radiotherapy Platform

MIDDLETON, Wis., July 29, 2025 /PRNewswire/ -- Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship…

4 months ago

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

July 25, 2025 16:05 ET  | Source: Celcuity Inc. MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC),…

4 months ago

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…

5 months ago

Bridge Capture enables sensitive, scalable liquid biopsy in colorectal cancer pilot

Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU,…

5 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and…

5 months ago

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…

5 months ago

‘Haven of Hope’ – Shelter Home for Underprivileged Cancer Patients Inaugurated in Kochi

The 'Haven of Hope' building, built under South Indian Bank's CSR initiative for underprivileged cancer patients, is now operational.A new…

5 months ago